Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Guard Therapeutics

1,25 SEK

-7,06 %

Mindre end 1K følgere

GUARD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-7,06 %
-9,09 %
-94,54 %
-93,52 %
-93,25 %
-94,18 %
-97,10 %
-97,91 %
-99,93 %

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Læs mere
Markedsværdi
25,21 mio. SEK
Aktieomsætning
28,59 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
20.2
2026

Årsrapport '25

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 10 timer siden

Guard Therapeutics Explores Strategic Alternatives

Guard Therapeutics
Pressemeddelelsefor 10 timer siden

Guard Therapeutics Provides Assessment of Full POINTER Study Results

Guard Therapeutics
Pressemeddelelse13.11.2025, 16.17

DNB Carnegie Access: Guard Therapeutics: Awaiting further company communication – Q3 review

Guard Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse27.10.2025, 08.33

DNB Carnegie Access: Guard Therapeutics: POINTER data – endpoints not met

Guard Therapeutics
Selskabsmeddelelse26.10.2025, 10.45

Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study

Guard Therapeutics
Pressemeddelelse17.10.2025, 06.00

Guard Therapeutics to Present Late-Breaking Phase 2b POINTER Results at ASN Kidney Week 2025

Guard Therapeutics
Selskabsmeddelelse5.10.2025, 12.15

Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study

Guard Therapeutics
Pressemeddelelse30.9.2025, 10.22

DNB Carnegie Access: Guard Therapeutics: POINTER data preview: high risk, high potential reward - corrected version

Guard Therapeutics
Pressemeddelelse29.9.2025, 05.07

DNB Carnegie Access: Guard Therapeutics: POINTER data preview: high risk, high potential reward

Guard Therapeutics
Pressemeddelelse11.9.2025, 15.10

Guard Therapeutics announces completion of data collection in Phase 2b POINTER study

Guard Therapeutics
Pressemeddelelse11.9.2025, 08.46

Redeye: Redeye Initiates Coverage of Guard Therapeutics

Guard Therapeutics
Pressemeddelelse2.9.2025, 14.24

DNB Carnegie Access: Guard Therapeutics: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Guard Therapeutics
Pressemeddelelse28.8.2025, 11.00

Guard Therapeutics presents additional AKITA results at leading U.S. nephrology conference

Guard Therapeutics
Pressemeddelelse22.8.2025, 11.10

Guard Therapeutics to present at upcoming investor conferences

Guard Therapeutics
Selskabsmeddelelse21.8.2025, 06.30

Guard Therapeutics publishes interim report January–June 2025

Guard Therapeutics
Pressemeddelelse5.6.2025, 06.45

Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study

Guard Therapeutics
Pressemeddelelse28.5.2025, 13.45

DNB Carnegie Access: Guard Therapeutics: Intervju - Positivt utfall i säkerhetsutvärdering

Guard Therapeutics
Selskabsmeddelelse27.5.2025, 17.30

Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study

Guard Therapeutics
Pressemeddelelse21.5.2025, 07.30

Guard Therapeutics to present Phase 2b POINTER study design at scientific conference

Guard Therapeutics
Pressemeddelelse14.5.2025, 05.34

DNB Carnegie Access: Guard Therapeutics: Transformative 12 months ahead

Guard Therapeutics
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.